Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOsteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
The molecular understanding of osteoclast differentiation
Asagiri, M., & Takayanagi, H. (2007) · Bone · doi:10.1016/j.bone.2006.09.023 · Cited by 1,363
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,263
Osteoblast-Osteoclast Communication and Bone Homeostasis
Kim, J.-M., Lin, C., Stavre, Z., Greenblatt, M. B., & Shim, J.-H. (2020) · Cells · doi:10.3390/cells9092073 · Cited by 1,178
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citationSambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.-E. B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 734
Self-citationDenosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
Richards, J., Rivadeneira, F., Inouye, M., Pastinen, T., Soranzo, N., Wilson, S., Andrew, T., Falchi, M., Gwilliam, R., Ahmadi, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60599-1 · Cited by 682
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Self-citationBrown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
Self-citationCohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23417 · Cited by 576
Self-citationGnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 559
An overview of the regulation of bone remodelling at the cellular level
Kular, J., Tickner, J., Chim, S. M., & Xu, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.021 · Cited by 534
Current understanding of periodontal disease pathogenesis and targets for host‐modulation therapy
Hajishengallis, G., Chavakis, T., & Lambris, J. D. (2020) · Periodontology 2000 · doi:10.1111/prd.12331 · Cited by 502
Fizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J. R., Gao, G., Wu, L., Sohn, W., & Jun, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2146 · Cited by 533
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Osteoimmunology and the effects of the immune system on bone
Takayanagi, H. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.217 · Cited by 487
Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., & Jun, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3832 · Cited by 483
Mundy, G. R. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00353.x · Cited by 478
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Kostenuik, P. J., Nguyen, H. Q., McCabe, J., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R. C., Van, G., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 443
Genetic architecture: the shape of the genetic contribution to human traits and disease
Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J., & Richards, J. B. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.101 · Cited by 434
Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-09-047712 · Cited by 433
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Self-citationBone metastasis: mechanisms and therapeutic opportunities
Suva, L. J., Washam, C., Nicholas, R. W., & Griffin, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.227 · Cited by 424
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391
Tsourdi, E., Zillikens, M. C., Meier, C., Body, J.-J., Gonzalez Rodriguez, E., Anastasilakis, A. D., Abrahamsen, B., McCloskey, E., Hofbauer, L. C., Guañabens, N., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa756 · Cited by 375
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics
Feldmann, M., & Maini, S. R. N. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00626.x · Cited by 381
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
A single-dose study of denosumab in patients with various degrees of renal impairment
Block, G. A., Bone, H. G., Fang, L., Lee, E., & Padhi, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1613 · Cited by 340
Vascular calcification and bone disease: the calcification paradox
Persy, V., & D’Haese, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.001 · Cited by 332
Mori, T., Miyamoto, T., Yoshida, H., Asakawa, M., Kawasumi, M., Kobayashi, T., Morioka, H., Chiba, K., Toyama, Y., & Yoshimura, A. (2011) · International Immunology · doi:10.1093/intimm/dxr077 · Cited by 328
The Biology of Aseptic Osteolysis
Holt, G., Murnaghan, C., Reilly, J., & Meek, R. M. D. (2007) · Clinical Orthopaedics & Related Research · doi:10.1097/blo.0b013e31804b4147 · Cited by 319
Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
Self-citationNuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.81 · Cited by 286
on behalf of the DAPS Investigators, Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., & Kendler, D. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1780-1 · Cited by 288
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
The osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 275
Weitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Eastell, R., Christiansen, C., Grauer, A., Kutilek, S., Libanati, C., McClung, M. R., Reid, I. R., Resch, H., Siris, E., Uebelhart, D., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.251 · Cited by 256
Self-citationDenosumab treatment for fibrous dysplasia
Boyce, A. M., Chong, W. H., Yao, J., Gafni, R. I., Kelly, M. H., Chamberlain, C. E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J. Z., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1603 · Cited by 260
Pathogenesis and management of Paget's disease of bone
Ralston, S. H., Langston, A. L., & Reid, I. R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61035-1 · Cited by 260
Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Mellström, D., Radominski, S. C., Reginster, J.-Y., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 254
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Reid, I. R., Miller, P. D., Brown, J. P., Kendler, D. L., Fahrleitner-Pammer, A., Valter, I., Maasalu, K., Bolognese, M. A., Woodson, G., Bone, H., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.149 · Cited by 251
Self-citationEstrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
Szulc, P., Seeman, E., Duboeuf, F., Sornay-Rendu, E., & Delmas, P. D. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060904 · Cited by 240
Physiological and pathophysiological bone turnover — role of the immune system
Weitzmann, M. N., & Ofotokun, I. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.91 · Cited by 240
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity?
Karsdal, M. A., Martin, T. J., Bollerslev, J., Christiansen, C., & Henriksen, K. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070109 · Cited by 242
Bollerslev, J., Rejnmark, L., Zahn, A., Heck, A., Appelman‐Dijkstra, N. M., Cardoso, L., Hannan, F. M., Cetani, F., Sikjær, T., Formenti, A. M., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-1044 · Cited by 274
Advances in osteoclast biology: old findings and new insights from mouse models
Edwards, J. R., & Mundy, G. R. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.23 · Cited by 235
Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1569 · Cited by 232
Self-citationJakobovits, A., Amado, R. G., Yang, X., Roskos, L., & Schwab, G. (2007) · Nature Biotechnology · doi:10.1038/nbt1337 · Cited by 230
Henriksen, K., Bollerslev, J., Everts, V., & Karsdal, M. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0006 · Cited by 230
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 219
Charatcharoenwitthaya, N., Khosla, S., Atkinson, E. J., McCready, L. K., & Riggs, B. L. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070207 · Cited by 235
Observations following discontinuation of long-term denosumab therapy
McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., & Lewiecki, E. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3919-1 · Cited by 227
Self-citationOsteonecrosis of the jaws induced by anti-RANK ligand therapy
Taylor, K. H., Middlefell, L. S., & Mizen, K. D. (2010) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2009.08.030 · Cited by 228
Boonen, S., Adachi, J. D., Man, Z., Cummings, S. R., Lippuner, K., Törring, O., Gallagher, J. C., Farrerons, J., Wang, A., Franchimont, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2784 · Cited by 220
Self-citationOsteoclasts, rheumatoid arthritis, and osteoimmunology
Sato, K., & Takayanagi, H. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231912.24740.a5 · Cited by 223
Pharmacology of bisphosphonates
Cremers, S., & Papapoulos, S. (2011) · Bone · doi:10.1016/j.bone.2011.01.014 · Cited by 217
Gerstenfeld, L. C., Sacks, D. J., Pelis, M., Mason, Z. D., Graves, D. T., Barrero, M., Ominsky, M. S., Kostenuik, P. J., Morgan, E. F., & Einhorn, T. A. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081113 · Cited by 218
Osteoimmunology: Crosstalk Between the Immune and Bone Systems
Nakashima, T., & Takayanagi, H. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9316-6 · Cited by 216
Szulc, P., & Delmas, P. D. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0660-9 · Cited by 220
RANKL/OPG; Critical role in bone physiology
Martin, T. J., & Sims, N. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9308-6 · Cited by 213
Binder, N. B., Niederreiter, B., Hoffmann, O., Stange, R., Pap, T., Stulnig, T. M., Mack, M., Erben, R. G., Smolen, J. S., & Redlich, K. (2009) · Nature Medicine · doi:10.1038/nm.1945 · Cited by 206
Bone turnover markers in the management of postmenopausal osteoporosis
Brown, J. P., Albert, C., Nassar, B. A., Adachi, J. D., Cole, D., Davison, K. S., Dooley, K. C., Don-Wauchope, A., Douville, P., Hanley, D. A., et al. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.04.001 · Cited by 204
RANK, RANKL and osteoprotegerin in bone biology and disease
Wright, H. L., McCarthy, H. S., Middleton, J., & Marshall, M. J. (2009) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-009-9046-7 · Cited by 194
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Peterson, M. C., & Riggs, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.08.053 · Cited by 198
Self-citationFully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease
Kiechl, S., Werner, P., Knoflach, M., Furtner, M., Willeit, J., & Schett, G. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.6.801 · Cited by 195
Dore, R. K., Cohen, S. B., Lane, N. E., Palmer, W., Shergy, W., Zhou, L., Wang, H., Tsuji, W., & Newmark, R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.112920 · Cited by 194
Self-citationGoëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention
Karmakar, S., Kay, J., & Gravallese, E. M. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.03.003 · Cited by 186
Santini, D., Schiavon, G., Vincenzi, B., Gaeta, L., Pantano, F., Russo, A., Ortega, C., Porta, C., Galluzzo, S., Armento, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019234 · Cited by 185
The RANK/RANKL/OPG triad in cancer-induced bone diseases
Dougall, W. C., & Chaisson, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 187
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.